These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15941429)

  • 1. Infectious complications of tumor necrosis factor-alpha antagonists.
    Bakleh M; Tleyjeh I; Matteson EL; Osmon DR; Berbari EF
    Int J Dermatol; 2005 Jun; 44(6):443-8. PubMed ID: 15941429
    [No Abstract]   [Full Text] [Related]  

  • 2. Serious infections associated with anticytokine therapies in the rheumatic diseases.
    Giles JT; Bathon JM
    J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.
    Wood KL; Hage CA; Knox KS; Kleiman MB; Sannuti A; Day RB; Wheat LJ; Twigg HL
    Am J Respir Crit Care Med; 2003 May; 167(9):1279-82. PubMed ID: 12615627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of infections with biological agents.
    Kopylov U; Afif W
    Gastroenterol Clin North Am; 2014 Sep; 43(3):509-24. PubMed ID: 25110256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.
    Jain VV; Evans T; Peterson MW
    Respir Med; 2006 Jul; 100(7):1291-3. PubMed ID: 16545951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe fungal infections linked to drugs.
    Kuehn BM
    JAMA; 2008 Oct; 300(14):1639. PubMed ID: 18840827
    [No Abstract]   [Full Text] [Related]  

  • 8. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
    Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
    Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
    [No Abstract]   [Full Text] [Related]  

  • 9. Tuberculosis infections and tumor necrosis factor alpha antagonists.
    Gan J; Manadan AM; Sequiera W; Block JA
    Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graves' disease, rheumatoid arthritis, and anti-tumor necrosis factor-alpha therapy.
    Shin JI; Kim MJ; Lee JS
    J Rheumatol; 2009 Feb; 36(2):449-50; author reply 450. PubMed ID: 19208577
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor necrosis factor blockers and reactivation of latent tuberculosis.
    Keane J
    Clin Infect Dis; 2004 Aug; 39(3):300-2. PubMed ID: 15306994
    [No Abstract]   [Full Text] [Related]  

  • 13. TNF-alpha antagonists: pulmonary legionellosis.
    Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
    Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
    Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
    Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases.
    Ubriani R; Van Voorhees AS
    Arch Dermatol; 2007 Feb; 143(2):270-2. PubMed ID: 17310016
    [No Abstract]   [Full Text] [Related]  

  • 18. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al.
    Scrivo R; Spadaro A; Spinelli FR; Valesini G
    Arthritis Rheum; 2008 May; 58(5):1555-6; author reply 1556-7. PubMed ID: 18438848
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al.
    Sfikakis PP; Markomichelakis N
    Arthritis Rheum; 2008 May; 58(5):1554-5; author reply 1556-7. PubMed ID: 18438832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.